--- title: "Anondita Medicare (758740) — Share Price, Financials & Analysis" symbol: "758740" company: "Anondita Medicare" canonical: "https://tapetide.com/stocks/758740" isin: "INE0VTV01012" nse_symbol: "ANONDITA" sector: "Consumer Goods" industry: "Personal Care" market_cap_cr: 2106.35 generated_at: "2026-09-13T19:38:59.630Z" --- # Anondita Medicare (758740) Canonical page: https://tapetide.com/stocks/758740 ## Company - **NSE Symbol:** ANONDITA - **ISIN:** INE0VTV01012 - **Sector:** Consumer Goods - **Industry:** Personal Care - **Stock Type:** EQUITY - **Listed Since:** 2025-09-01 - **F&O Eligible:** No ## Latest Price - **Price:** ₹1129.55 - **Change:** +1.15 (+0.1%) - **Open:** ₹1110 - **Day High:** ₹1164.5 - **Day Low:** ₹1100.15 - **Previous Close:** ₹1128.4 - **Volume:** 52800 - **As Of:** 2026-09-11T09:59:44+00:00 ## Key Fundamentals Observed at 2026-09-11T04:47:43.051458Z. - **Market Cap:** ₹2106.35 Cr - **Classification:** SME - **P/E (reported):** 62.7 - **Book Value:** ₹115.65 - **Price to Book:** 9.76 - **Dividend Yield:** 0% - **ROE:** 42.04% - **ROCE:** 48.42% - **Debt to Equity:** 0.71 - **Revenue (yearly):** ₹137.42 Cr - **Net Income:** ₹36.15 Cr - **EBITDA:** ₹50.67 Cr - **52-Week High:** ₹1316 - **52-Week Low:** ₹323.8 - **RSI (14):** 55.98 ## Tapetide Score - **Score:** 65 / 100 - **Score date:** 2026-09-04 - **Percentile:** 96.7 (of 4473 scored stocks) - **Confidence:** 64% - **Data coverage:** 62% | Pillar | Score | Weight | | --- | --- | --- | | financial health | 46.13 | 13.04% | | momentum | 85.6 | 17.39% | | ownership | 98.9 | 34.78% | | valuation | 32.33 | 34.78% | The Tapetide Score is decision-support only, not investment advice. ## Growth Rates | Metric | 1Y | 3Y | 5Y | | --- | --- | --- | --- | | cash flow growth | -181.67% | -359.16% | -303.7% | | ebitda margin growth | 9.6% | — | — | | net income growth | 120.43% | — | — | | revenue growth | 78.24% | — | — | ## Financial Statements ### Quarterly Results All figures in ₹ crore unless the row name says otherwise. | Item | Sep 2024 | Sep 2025 | | --- | --- | --- | | Sales | 31 | 54 | | Expenses | 22 | 35 | | Operating Profit | 10 | 19 | | OPM % | 31 | 35 | | Other Income | 0 | 0 | | Interest | 1 | 2 | | Depreciation | 0 | 0 | | Profit before tax | 8 | 17 | | Tax % | 25 | 25 | | Net Profit | 6 | 13 | | EPS in Rs | 4.29 | 7.11 | ### Profit & Loss All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2025 | | --- | --- | | Sales | 77 | | Expenses | 51 | | Operating Profit | 26 | | OPM % | 33 | | Other Income | 0 | | Interest | 3 | | Depreciation | 1 | | Profit before tax | 22 | | Tax % | 25 | | Net Profit | 16 | | EPS in Rs | 11.88 | | Dividend Payout % | 0 | ### Balance Sheet All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2025 | Sep 2025 | | --- | --- | --- | | Equity Capital | 13 | 18 | | Reserves | 25 | 91 | | Borrowings | 27 | 47 | | Other Liabilities | 13 | 21 | | Total Liabilities | 78 | 176 | | Fixed Assets | 14 | 13 | | CWIP | 6 | 15 | | Investments | 3 | 3 | | Other Assets | 55 | 145 | | Total Assets | 78 | 176 | ### Cash Flow All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2025 | | --- | --- | | Cash from Operating Activity | -10 | | Cash from Investing Activity | -23 | | Cash from Financing Activity | 33 | | Net Cash Flow | 0 | ### Ratios | Item | Mar 2025 | | --- | --- | | Debtor Days | 127 | | Inventory Days | 141 | | Days Payable | 40 | | Cash Conversion Cycle | 228 | | Working Capital Days | 129 | ## Shareholding Pattern ### Quarterly | Category | Dec 2024 | Sep 2025 | Mar 2026 | | --- | --- | --- | --- | | Promoters | 83.95% | 61.79% | 62.4% | | FIIs | 0% | 4.24% | 3.4% | | DIIs | 0% | 0% | 5.7% | | Government | 0% | 0% | 0% | | Public | 0% | 17.13% | 18.84% | | Others | 16.05% | 16.84% | 9.65% | | No. of Shareholders | 57 | 621 | 530 | ## Technical Indicators Derived from daily closing prices and recomputed each trading session; values move with the market. - **Overall Signal:** Strong Buy - **Buy / Neutral / Sell:** 12 / 7 / 0 ### Moving Averages — summary: **Strong Buy** | Indicator | Value | Signal | | --- | --- | --- | | SMA (10) | 1112.66 | Buy | | EMA (10) | 1117.48 | Buy | | SMA (20) | 1087.03 | Buy | | EMA (20) | 1101.67 | Buy | | SMA (50) | 1100.72 | Buy | | EMA (50) | 1093.71 | Buy | | SMA (100) | 1099.51 | Buy | | EMA (100) | 1046.62 | Buy | | SMA (200) | 921.74 | Buy | | EMA (200) | 882.97 | Buy | ### Oscillators — summary: **Buy** | Indicator | Value | Signal | | --- | --- | --- | | RSI (14) | 55.67 | Neutral | | MACD (12,26,9) | 14.02 | Buy | | Stochastic (14,3,3) | 70.96 | Neutral | | ADX (14) | 24.76 | Neutral | | Williams %R (14) | -31.4 | Neutral | | ATR (14) | 58.55 | High Volatility | | ROC (12) | 8.23 | Buy | | Stoch RSI (14) | 62.57 | Neutral | | UO (7,14,28) | 53.96 | Neutral | ## Filings & Documents ### Other Documents | Date | Document | | --- | --- | | 9 March 2026 - Management participated virtually in Arihant Capital Bharat Connect Conference on March 9, 2026; no UPSI disclosed. | [Updates 9 March 2026 - Management participated virtually in Arihant Capital Bharat Connect Conference on March 9, 2026; no UPSI disclosed.](https://nsearchives.nseindia.com/corporate/ANONDITA_09032026225100_Outcome_of_participation_in_investor_meet_signed.pdf) | | 9 July 2026 - Company clarifies FY26 results query; revised EPS 11.38/20.77 filed May 29, 2026. | [Reply to Clarification- Financial results 9 July 2026 - Company clarifies FY26 results query; revised EPS 11.38/20.77 filed May 29, 2026.](https://nsearchives.nseindia.com/corporate/ANONDITA_26062026135229_AML_NSE_reply_on_Query_for_Finanical_Result_FY26.pdf) | | 8 July 2026 - Anondita Medicare schedules in-person investor meeting in Mumbai on 11 July 2026. | [Analysts/Institutional Investor Meet/Con. Call Updates 8 July 2026 - Anondita Medicare schedules in-person investor meeting in Mumbai on 11 July 2026.](https://nsearchives.nseindia.com/corporate/ANONDITA_08072026160944_Signed_Intimation_of_Investor_Group_Meet_11_July_2026.pdf) | | 8 July 2026 - Anondita Medicare Limited has informed regarding Outcome of Board Meeting held on July 08, 2026 with respect to Allotment of Convertible Warrants. | [Outcome of Board Meeting 8 July 2026 - Anondita Medicare Limited has informed regarding Outcome of Board Meeting held on July 08, 2026 with respect to Allotment of Convertible Warrants.](https://nsearchives.nseindia.com/corporate/ANONDITA_08072026132447_Outcome_of_Board_Meeting.pdf) | | 8 July 2026 - Anondita Medicare Limited has informed regarding allotment of 285000 Convertible Warrants on Preferential basis at its meeting held on July 08, 2026 | [Allotment of Securities 8 July 2026 - Anondita Medicare Limited has informed regarding allotment of 285000 Convertible Warrants on Preferential basis at its meeting held on July 08, 2026](https://nsearchives.nseindia.com/corporate/ANONDITA_08072026133432_Disclosure_under_section_30.pdf) | | 7 May 2026 - Published EGM notice in newspapers; EGM scheduled for May 28, 2026 via VC/OAVM. | [Copy of Newspaper Publication 7 May 2026 - Published EGM notice in newspapers; EGM scheduled for May 28, 2026 via VC/OAVM.](https://nsearchives.nseindia.com/corporate/ANONDITA_07052026134936_Signed_Intimation_of_Newspaper_Advertisemtent_7_May_2026.pdf) | | 7 March 2026 - MD Anupam Ghosh honored with Leadership Award by Lok Sabha Speaker on March 7, 2026; event on sustainability. | [Updates 7 March 2026 - MD Anupam Ghosh honored with Leadership Award by Lok Sabha Speaker on March 7, 2026; event on sustainability.](https://nsearchives.nseindia.com/corporate/ANONDITA_07032026191059_Intimation_to_stock_exchange_Award_sd.pdf) | | 7 March 2026 - Filed investor presentation for Arihant Capital conference on March 9, 2026; highlights ₹75 crore expansion, MDSAP and SABS certifications. | [Updates 7 March 2026 - Filed investor presentation for Arihant Capital conference on March 9, 2026; highlights ₹75 crore expansion, MDSAP and SABS certifications.](https://nsearchives.nseindia.com/corporate/ANONDITA_07032026120943_Regulation_30_Investor_Presentation.pdf) | | 6 May 2026 - EGM on May 28, 2026 to approve ₹29.13 crore promoter warrants, related-party transactions, and remuneration hikes. | [Shareholders meeting 6 May 2026 - EGM on May 28, 2026 to approve ₹29.13 crore promoter warrants, related-party transactions, and remuneration hikes.](https://nsearchives.nseindia.com/corporate/ANONDITA_06052026181703_AML_Notice_of_EGM_with_Cover_letter.pdf) | | 6 July 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 6 July 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/ANONDITA_06072026174649_Compliance_Certificate_under_Regulation_74_5__signed.pdf) | ### Earnings Call Documents | Date | Document | | --- | --- | | Sep 2023 | [Concall - Sep 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/792670ef-cdb4-472f-8f38-35ba01e129a4.pdf) | | Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2facb771-7c79-411d-854c-5fb306fa9ca9.pdf) | | May 2026 | [Concall - May 2026](https://nsearchives.nseindia.com/corporate/ANONDITA_27052026140858_AML_Intimation_of_Investor_Presentation_H2FY26.pdf) | | May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/34f597b2-2db7-424e-92cd-7d70dcab576f.pdf) | | Jan 2023 | [Concall - Jan 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/88239522-a7ef-40f1-9b42-e9b7afce0335.pdf) | | Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33ff446c-f718-4746-bb04-518acaa93ce2.pdf) | | Apr 2024 | [Concall - Apr 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4711a4c9-0312-4554-af29-f94e4ec4ae0e.pdf) | ### Annual Reports | Date | Document | | --- | --- | | from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75f377e9-dd59-4858-a817-02276a9e8c1a.pdf) | | from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3ed25312-6a40-493a-99d4-5d998de2e609.pdf) | | from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/40be5cc0-f133-4bd3-8191-efd47da32b02.pdf) | | from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/74636530677.pdf) | | from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/71620530677.pdf) | | from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/66750530677.pdf) | | from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/5306770319.pdf) | | from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/5306770318.pdf) | | from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/5306770317.pdf) | | from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/530677/5306770316.pdf) | --- Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:59.630Z.